In today’s briefing:
- Acadia Healthcare Company Inc.: Initiation Of Coverage – Investment in technology to optimize infrastructure and clinical outcomes! – Major Drivers
- Tenet Healthcare Corporation: Initiation Of Coverage – Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! – Major Drivers
- Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage – Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! – Major Drivers
- DENTSPLY SIRONA Inc.: Initiation Of Coverage – What Is Its Core Business Strategy? – Major Drivers
- Elanco Animal Health: Initiation Of Coverage – A Story Of Concentration on Pet Health and Livestock Sustainability! – Major Drivers
- Fresenius Medical Care: Initiation Of Coverage – Innovation with AR in Dialysis Training & 4 Other Major Drivers
- Globus Medical Inc.: Initiation Of Coverage – Increasing Portfolio Range & 3 Critical Growth Factors
- Ionis Pharmaceuticals Inc.: Initiation Of Coverage – Its New wholly-owned medicines and Independent launches Can Catalyze Growth? – Major Drivers
- Medpace Holdings Inc.: Initiation Of Coverage – Does It Have A Sustainable Competitive Advantage? – Major Drivers
- Neurocrine Biosciences Inc.: Initiation Of Coverage – Continued Investment & Growth for INGREZZA Paving The Way Forward? – Major Drivers
Acadia Healthcare Company Inc.: Initiation Of Coverage – Investment in technology to optimize infrastructure and clinical outcomes! – Major Drivers
- Acadia Healthcare delivered a robust financial performance for 2023, marked by a 12.2% annual revenue growth, 13.1% adjusted EBITDA growth, and 14.3% adjusted EPS growth compared to 2022.
- In the fourth quarter, its same-facility revenue rose by 10.3% on the back of rate improvements and patient day growth.
- Acadia also saw consistent improvement in its labor trends throughout 2023.
Tenet Healthcare Corporation: Initiation Of Coverage – Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! – Major Drivers
- Tenet Healthcare’s Q4 2023 earnings indicated a strong performance, with net operating revenues of $20.5 billion, and consolidated adjusted EBITDA of $3.54 billion, which translates into an attractive 17.2% adjusted EBITDA margin.
- The company has demonstrated its ability to maintain profitability while focusing on quality and innovation.
- Yet, some challenges were also mentioned during the earnings call.
Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage – Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! – Major Drivers
- Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7% increase in admissions over the prior year period and an average daily census of 1,918.
- This is an 11% increase in comparison to the prior year and suggests that a hiring and retention program initiated in 2022 to remedy any potential worker turnover and expand clinical workforce capacity has been successful in maintaining VITAS’ operational performance.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
DENTSPLY SIRONA Inc.: Initiation Of Coverage – What Is Its Core Business Strategy? – Major Drivers
- Examining the fourth quarter 2023 earnings for Dentsply Sirona reveals an investment thesis that emphasizes the company’s successful strategies, robust performance and rigorous financial discipline, alongside ambitious future business growth targets and consistent value creation for its stakeholders.
- Starting with the positives, Dentsply Sirona achieved over 2% organic sales growth for 2023, outperforming projections via growth in three of its four business segments.
- Notably, its orthodontic business experienced double-digit growth with both Byte and SureSmile.
Elanco Animal Health: Initiation Of Coverage – A Story Of Concentration on Pet Health and Livestock Sustainability! – Major Drivers
- In Q4 2023, Elanco Animal Health reported a 5% constant currency revenue growth, driven by innovations, the strength of the farm animal business, improved conditions in the European Pet Health retail market, and increased pricing.
- The strong performance in 2023 indicates that the company’s innovation, portfolio, and productivity strategy are working, leading to confidence in the potential success of future investments.
- Going into 2024, the company aims to focus on three priorities: sustained revenue growth, innovation, and improved cash conversion.
Fresenius Medical Care: Initiation Of Coverage – Innovation with AR in Dialysis Training & 4 Other Major Drivers
- Fresenius Medical Care’s Q4 2023 earnings highlighted the progress made against their strategic plan that was set out a year prior.
- The plan focused on significant structural, operational and cultural changes, with the operating model being transformed at the start of 2023.
- This allowed the company to introduce a new financial report with increased transparency, which reflected a commitment to their operational turnaround initiatives that aided organic growth in both segments and improved operational performance.
Globus Medical Inc.: Initiation Of Coverage – Increasing Portfolio Range & 3 Critical Growth Factors
- Globus Medical, a leading musculoskeletal solutions provider, has reported record revenues of $1.569 billion for the full year 2023, marking a growth of 53% compared to the previous year.
- The strong performance includes four months of sales after its merger with NuVasive.
- This remarkable growth maintained the company’s industry-leading profitability, generating a record non-GAAP EPS of $2.32 and an adjusted EBITDA of 30%.
Ionis Pharmaceuticals Inc.: Initiation Of Coverage – Its New wholly-owned medicines and Independent launches Can Catalyze Growth? – Major Drivers
- Ionis Pharmaceuticals Inc. had a remarkable year in 2023, with significant advancements in their RNA targeting platform and a steady stream of upcoming independent medicines delivering directly to patients.
- The company’s forward-looking stratagem involves expanding their technology and broadening its applicability to cater to patients’ needs.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
Medpace Holdings Inc.: Initiation Of Coverage – Does It Have A Sustainable Competitive Advantage? – Major Drivers
- Medpace Holdings, a leading full-service clinical contract research organization (CRO), reported robust results for the fourth quarter and full year of 2023.
- The company’s revenue increased 26.5% year-over-year in Q4, reaching $498.4 million.
- For the full year, revenue stood at $1.89 billion, a rise of 29.2% from 2022.
Neurocrine Biosciences Inc.: Initiation Of Coverage – Continued Investment & Growth for INGREZZA Paving The Way Forward? – Major Drivers
- Neurocrine Biosciences Inc, a biopharmaceutical company specializing in neurologic, psychiatric, and endocrine related disorders, showed significant growth during its remarkable year of 2023.
- According to Neurocrine’s executives, the firm’s performance reflected the ongoing progress and the successful execution of business strategies with nearly 30% year-over-year sales growth for its flagship product, INGREZZA, which is a drug indicated for the treatment of tardive dyskinesia in adults.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
